Home | Journal for ImmunoTherapy of Cancer

Latest Articles

Correction: Total metabolic tumor volume on 18F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system
Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination
Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using ⁹⁰Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors

Case report

Spontaneous tumor regression following COVID-19 vaccination(3 March, 2022)
Position article and guidelines

Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy(29 February, 2024)
Immune cell therapies and immune cell engineering

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study(13 December, 2022)
Clinical/translational cancer immunotherapy

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial(12 February, 2024)
Commentary

CARs are sharpening their weapons(31 January, 2024)